USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: PHRIXUS PHARMACEUTICALS, INC.
City: ANN ARBOR
State: MI
Zip+4: 48104-
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,078,319.00 5
STTR Phase I $306,708.00 1

Award List:

Chronic Treatment of Heart Failure With Poloxamer-188

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce E. Markham
Award Amount: $215,084.00
Abstract:
DESCRIPTION (provided by applicant): Heart failure (HF) is a major medical problem in the United States affecting more than 5 million patients. It is expected to impact 11 million patients by 2011. Of these patients, over 40% have a defect in the ability o f the heart muscle to relax which prevents… More

Poloxamer-188 for the prevention of fibrosis during peritoneal dialysis

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce E. Markham
Award Amount: $277,646.00
Abstract:
DESCRIPTION (provided by applicant): Project Summary. This application is focused on preventing adverse events associated with chronic peritoneal dialysis (PD), a renal replacement therapy for end stage renal disease (ESRD). PD as a renal r eplacement therapy is the method of choice… More

Development of Poloxamer-188 for the Treatment of Muscular Dystrophy Associated H

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce E. Markham
Award Amount: $379,487.00
Abstract:
DESCRIPTION (provided by applicant): This application focuses on initial preclinical steps required to develop Poloxamer-188 (P-188) for the treatment of heart failure (HF) associated with Duchene and Becker Muscular Dystrophy (MD). Dr. Joe Metzger and col leagues (Yasuda et al., 2005) demonstrated… More

Poloxamer 188 mechanism of action in ischemic heart failure.

Award Year / Program / Phase: 2010 / STTR / Phase I
Agency: HHS
Research Institution: University Of Minnesota
Principal Investigator: Bruce E. Markham – 248-921-8226
Award Amount: $306,708.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): This project was initiated to determine how Poloxamer-188 (P-188) improves cardiac function in ischemic heart failure (HF). While it is accepted that lack of oxygen (ischemia) results in tissue damage, the direct involvement of membrane injury in the progression… More

Effects of P-188 on Respiratory Function and Diaphragm Degeneration in the mdx mo

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce E. Markham – 248-921-8226
Award Amount: $583,225.00
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this project is to develop Poloxamer-188 (P-188) for the delay or prevention of respiratory deficits in patients with Duchenne muscular dystrophy (DMD). Phrixus Pharmaceuticals Inc. is also developing P-188 for the treatment of acute… More

Treatment of Muscular Dystrophy-associated Dilated Cardiomyopathy with P-188

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce E. Markham – 248-921-8226
Award Amount: $622,877.00
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this project is to obtain FDA approval to market Poloxamer-188 (P- 188) for the prevention and treatment of dilated cardiomyopathy (DCM) and heart failure (HF) in Duchenne muscular dystrophy (DMD)patients. DMD is a debilitating and fatal… More